Skip to Main Content
 

COVID-19 / coronavirus FOAs (as of 6/5/20)

If you wish to submit to any of these programs, please contact your
Sponsored Programs Officer right away. 

NIH

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
(NOT-AI-20-030) for NIAID & NIGMS grantees - rescinded 4/8/20, replaced w/AI & GM NOSIs below

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
(NOT-HL-20-757) for NHLBI grantees, FAQs , expired 5/15/20  

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
(NOT-DA-20-047) for NIDA grantees 

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need
(NOT-TR-20-011) for CTSA awardees

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
(NOT-GM-20-025) for NIGMS grantees with SBIR/STTR awards

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-034) for NIAID awardees

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
(NOT-HG-20-030) for NHGRI awardees, May 15, 2020 deadline

Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-AI-20-031) from NIAID – rescinded 5/14/20, replaced with NOSI below

Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-AI-20-051) from NIAID

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
(NOT-AG-20-022) for NIA & NIMH awardees; NIA FAQs 

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)
(NOT-DC-20-004) for NIDCD awardees, 6/1/20 deadline

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK
(NOT-DK-20-018) for NIDDK awardees, 6/1/20 deadline

Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)
(NOT-CA-20-042) for NCI awardees, 6/24/20 deadline

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities
(NOT-MD-20-019) for NIMHD, NIA & NIMH awardees

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)
(NOT-AT-20-011) for NCCIH, NIA & NIAAA awardees

Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19
(NOT-GM-20-027) for NIGMS U24 awardees, 5/5/20 deadline

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences
(NOT-OD-20-097) for NCCIH, NCI, NHLBI, NIA, NIAAA, NIDDK awardees

Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2
(NOT-NS-20-046) for NINDS U01 or U24 data center awardees, 5/8/20 deadline 

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA
(NOT-AA-20-011) for NIAAA awardees

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs
(NOT-TR-20-028) for NCATS/CTSA awardees 

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-RM-20-015) for Common Fund awardees (e.g. DP2, R01, R35, U01, U54, etc)

NIH Rapid Acceleration of Diagnostics (RADx) Initiative for COVID-19
Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the NIH Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches.

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01)
(PAR-20-178) from NIAID; applications will be accepted on a rolling basis, beginning on 04/30/2020

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
(NOT-NS-20-051) for NINDS awardees 

NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-20-020) 9/30/2020 deadline, FAQs 

Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19)
(NOT-AT-20-012) for NCCIH awardees, 8/17/20 deadline

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
(NOT-DC-20-008) for due dates on or after 10/5/20

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations
(NOT-MD-20-022)


NIAID news articles (2/19/20, 4/1/20 & 4/15/20) on this topic

NIAID’s Multi-Pronged Response to the COVID-2019 Outbreak 

Updates on NIAID Funding for SARS-CoV-2 and COVID-2019 Research

NIAID’s Research Response to COVID-19  & Additional Accommodations Accompanying COVID-19 Pandemic Response


NIAID’s 2020 Omnibus Broad Agency Announcement (BAA) is soliciting research on emerging viruses and pandemics under Research Areas 3, 4 and 5. This covers highly pathogenic human coronaviruses: https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-025.html  

This NIAID contract program was announced in 2/10/20 funding alert:

Deadline

Program Title

Award Type

Sponsor

Amount

04/09/2020

2020 NIAID Omnibus Broad Agency Announcement

Details

Contract

NIH/NIAID

NIAID estimates that the average annual total cost is $2M per contract, however, the total cost may vary depending upon the scope of the project

Other related existing NIH programs:
Partnerships for Countermeasures against Select Pathogens (R01) due date 6/29/20
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.html from NIAID

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)
(NOT-TR-20-012) from NCATS various due dates in June 2020

NSF

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052) https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp
The National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov .

Other Federal agencies (applied research projects):

Biomedical Advanced Research and Development Authority (BARDA) BAA
https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

DOD/Dept of Army RFP for Development of Treatments for COVID-19 
enhanced white paper due April 8, 2020

DOD/Congressionally Directed Medical Research Programs (CDMRP)
FY20 Peer Reviewed Medical Research Program (PRMRP)

Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)
Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)
Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)
Various due dates in June  

DOD
Newton Award for Transformative Ideas during the COVID-19 Pandemic

This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. 5/15/20 deadline


Foundations / Other

The Wellcome Trust has a COVID-19 funding program too – up to £2 million for a 2 year project
https://wellcome.ac.uk/funding/schemes/epidemic-preparedness-covid-19

This program is currently closed. Note that their focus is on applicants from low/middle income countries, but they’re also interested in disease pathogenesis research too.

LifeArc Coronavirus (COVID-19) Therapeutics - initial £10M commitment for the identification of therapeutics that can be rapidly deployed to treat COVID-19; April 6, 2020 due date.

American Heart Association Rapid Response Grant COVID-19 and Its Cardiovascular Impact April 6, 2020 due date.

Emergent Ventures Fast Grants for COVID-19 Science - grant budgets range from $10K - $500K; $22M commitment from funders. This program is currently closed.

American Lung Association COVID-19 and Emerging Respiratory Viruses Research Award The award ($100K/year for 2 years) is intended to support independent investigators with a stellar track record of accomplishment, who have the potential to advance our knowledge of COVID-19 and other novel respiratory viruses with epidemic potential. May 30, 2020 deadline.

Gates Foundation COVID-19 Therapeutics Accelerator is a collaborative effort to research, develop and bring effective treatments to market quickly and accessibly. We are actively seeking and welcoming new partners and collaborators in this effort. This opportunity may involve intellectual property issues. Please contact Jeanne Farrell (Associate Vice President, jfarrell@rockefeller.edu) before submitting ideas.

American Diabetes Association COVID-19 and Diabetes Research Award for research focused on the impact of diabetes on COVID-19 and the impact of COVID-19 on diabetes and its complications. Funding at least 10 grants of up to $100,000 each. May 22, 2020 deadline. 

Pfizer Global Medical Grants  Vaccine Preventable Diseases – COVID-19 to support research to increase knowledge of COVID-19 epidemiology, infection, pathophysiology, and potential prevention measures.  $50,000 - $250,000/award; rolling deadline, RFP closes 6/17/2020